Structural basis of potent and broad HIV-1 fusion inhibitor CP32M
- PMID: 22679024
- PMCID: PMC3411002
- DOI: 10.1074/jbc.M112.381079
Structural basis of potent and broad HIV-1 fusion inhibitor CP32M
Abstract
CP32M is a newly designed peptide fusion inhibitor possessing potent anti-HIV activity, especially against T20-resistant HIV-1 strains. In this study, we show that CP32M can efficiently inhibit a large panel of diverse HIV-1 variants, including subtype B', CRF07_BC, and CRF01_AE recombinants and naturally occurring or induced T20-resistant viruses. To elucidate its mechanism of action, we determined the crystal structure of CP32M complexed with its target sequence. Differing from its parental peptide, CP621-652, the (621)VEWNEMT(627) motif of CP32M folds into two α-helix turns at the N terminus of the pocket-binding domain, forming a novel layer in the six-helix bundle structure. Prominently, the residue Asn-624 of the (621)VEWNEMT(627) motif is engaged in the polar interaction with a hydrophilic ridge that borders the hydrophobic pocket on the N-terminal coiled coil. The original inhibitor design of CP32M provides several intra- and salt bridge/hydrogen bond interactions favoring the stability of the helical conformation of CP32M and its interactions with N-terminal heptad repeat (NHR) targets. We identified a novel salt bridge between Arg-557 on the NHR and Glu-648 of CP32M that is critical for the binding of CP32M and resistance against the inhibitor. Therefore, our data present important information for developing novel HIV-1 fusion inhibitors for clinical use.
Figures







Similar articles
-
The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.J Virol. 2019 Dec 12;94(1):e01358-19. doi: 10.1128/JVI.01358-19. Print 2019 Dec 12. J Virol. 2019. PMID: 31619552 Free PMC article.
-
Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.J Biol Chem. 2012 Jun 8;287(24):20281-9. doi: 10.1074/jbc.M112.354126. Epub 2012 Apr 16. J Biol Chem. 2012. PMID: 22511760 Free PMC article.
-
Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem. 2012 Feb 24;287(9):6788-96. doi: 10.1074/jbc.M111.317883. Epub 2012 Jan 6. J Biol Chem. 2012. PMID: 22228771 Free PMC article.
-
Peptide and non-peptide HIV fusion inhibitors.Curr Pharm Des. 2002;8(8):563-80. doi: 10.2174/1381612024607180. Curr Pharm Des. 2002. PMID: 11945159 Review.
-
Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.Curr Pharm Des. 2013;19(10):1800-9. doi: 10.2174/1381612811319100004. Curr Pharm Des. 2013. PMID: 23092277 Review.
Cited by
-
Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.J Biol Chem. 2018 Aug 17;293(33):12703-12718. doi: 10.1074/jbc.RA118.003538. Epub 2018 Jun 21. J Biol Chem. 2018. PMID: 29929981 Free PMC article.
-
Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity.Biochim Biophys Acta. 2014 Sep;1838(9):2180-97. doi: 10.1016/j.bbamem.2014.04.015. Epub 2014 Apr 26. Biochim Biophys Acta. 2014. PMID: 24780375 Free PMC article. Review.
-
Entry Inhibitors: Efficient Means to Block Viral Infection.J Membr Biol. 2020 Oct;253(5):425-444. doi: 10.1007/s00232-020-00136-z. Epub 2020 Aug 30. J Membr Biol. 2020. PMID: 32862236 Free PMC article. Review.
-
Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.PLoS Pathog. 2019 Feb 4;15(2):e1007552. doi: 10.1371/journal.ppat.1007552. eCollection 2019 Feb. PLoS Pathog. 2019. PMID: 30716118 Free PMC article.
-
Python-driven impedance profiling on peptide-functionalized biosensor for detection of HIV gp41 envelope protein.3 Biotech. 2025 Jul;15(7):229. doi: 10.1007/s13205-025-04400-8. Epub 2025 Jun 30. 3 Biotech. 2025. PMID: 40599495 Free PMC article.
References
-
- Colman P. M., Lawrence M. C. (2003) The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4, 309–319 - PubMed
-
- Zhu P., Liu J., Bess J., Jr., Chertova E., Lifson J. D., Grisé H., Ofek G. A., Taylor K. A., Roux K. H. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847–852 - PubMed
-
- Eckert D. M., Kim P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777–810 - PubMed
-
- Chan D. C., Kim P. S. (1998) HIV entry and its inhibition. Cell 93, 681–684 - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources